46 related articles for article (PubMed ID: 10402973)
1. Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.
Guinovart C; Aponte JJ; Sacarlal J; Aide P; Leach A; Bassat Q; Macete E; Dobaño C; Lievens M; Loucq C; Ballou WR; Cohen J; Alonso PL
PLoS One; 2009; 4(4):e5165. PubMed ID: 19365567
[TBL] [Abstract][Full Text] [Related]
2. Current challenges and proposed solutions to the effective implementation of the RTS, S/AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review.
Dimala CA; Kika BT; Kadia BM; Blencowe H
PLoS One; 2018; 13(12):e0209744. PubMed ID: 30596732
[TBL] [Abstract][Full Text] [Related]
3. PfSPZ Vaccine learns a lesson.
Zaidi I; Duffy PE
Med; 2021 Dec; 2(12):1289-1291. PubMed ID: 35590146
[TBL] [Abstract][Full Text] [Related]
4. mRNA vaccine against malaria effective in preclinical model.
Makoni M
Lancet Microbe; 2023 Dec; 4(12):e970. PubMed ID: 37865114
[No Abstract] [Full Text] [Related]
5. First-generation malaria vaccine successfully implemented in three African countries.
Daubenberger CA; Silva JC
Lancet; 2024 Apr; 403(10437):1607-1609. PubMed ID: 38583452
[No Abstract] [Full Text] [Related]
6. Future use-cases of vaccines in malaria control and elimination.
Penny MA; Camponovo F; Chitnis N; Smith TA; Tanner M
Parasite Epidemiol Control; 2020 Aug; 10():e00145. PubMed ID: 32435704
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP.
Rampling T; Ewer KJ; Bowyer G; Edwards NJ; Wright D; Sridhar S; Payne R; Powlson J; Bliss C; Venkatraman N; Poulton ID; de Graaf H; Gbesemete D; Grobbelaar A; Davies H; Roberts R; Angus B; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee C; Ockenhouse C; Sinden RE; Gerry SC; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Lewis DJM; Cooke GS; Faust SN; Gilbert S; Hill AVS
NPJ Vaccines; 2018; 3():49. PubMed ID: 30323956
[TBL] [Abstract][Full Text] [Related]
8. Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective.
Curtidor H; Reyes C; Bermúdez A; Vanegas M; Varela Y; Patarroyo ME
Molecules; 2017 Dec; 22(12):. PubMed ID: 29231862
[TBL] [Abstract][Full Text] [Related]
9. The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial.
Guinovart C; Dobaño C; Bassat Q; Nhabomba A; Quintó L; Manaca MN; Aguilar R; Rodríguez MH; Barbosa A; Aponte JJ; Mayor AG; Renom M; Moraleda C; Roberts DJ; Schwarzer E; Le Souëf PN; Schofield L; Chitnis CE; Doolan DL; Alonso PL
PLoS One; 2012; 7(3):e32362. PubMed ID: 22412865
[TBL] [Abstract][Full Text] [Related]
10. A review of malaria vaccine clinical projects based on the WHO rainbow table.
Schwartz L; Brown GV; Genton B; Moorthy VS
Malar J; 2012 Jan; 11():11. PubMed ID: 22230255
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review.
Moorthy VS; Reed Z; Smith PG
Malar J; 2009 Feb; 8():23. PubMed ID: 19208236
[TBL] [Abstract][Full Text] [Related]
12. Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines.
Patarroyo ME; Cifuentes G; Bermúdez A; Patarroyo MA
J Cell Mol Med; 2008 Oct; 12(5B):1915-35. PubMed ID: 19012725
[TBL] [Abstract][Full Text] [Related]
13. Vaccines for preventing malaria (SPf66).
Graves P; Gelband H
Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD005966. PubMed ID: 16625647
[TBL] [Abstract][Full Text] [Related]
14. Integrated approach to malaria control.
Shiff C
Clin Microbiol Rev; 2002 Apr; 15(2):278-93. PubMed ID: 11932233
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania.
Acosta CJ; Galindo CM; Schellenberg D; Aponte JJ; Kahigwa E; Urassa H; Schellenberg JR; Masanja H; Hayes R; Kitua AY; Lwilla F; Mshinda H; Menendez C; Tanner M; Alonso PL
Trop Med Int Health; 1999 May; 4(5):368-76. PubMed ID: 10402973
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune responses during a malaria vaccine trial in Tanzanian infants.
Galindo CM; Acosta CJ; Schellenberg D; Aponte JJ; Roca A; Oettli A; Urassa H; Armstrong Schellenberg J; Kahigwa E; Ascaso C; Mshinda H; Lwilla F; Vidal J; Menendez C; Tanner M; Alonso PL
Parasite Immunol; 2000 Sep; 22(9):437-43. PubMed ID: 10972850
[TBL] [Abstract][Full Text] [Related]
17. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
[TBL] [Abstract][Full Text] [Related]
18. Safety in infants of SPf66, a synthetic malaria vaccine, delivered alongside the EPI.
Schellenberg DM; Acosta CJ; Galindo CM; Kahigwa E; Urassa H; Masanja H; Aponte JJ; Schellenberg JR; Fraser-Hurt N; Lwilla F; Menendez C; Mshinda H; Tanner M; Alonso PL
Trop Med Int Health; 1999 May; 4(5):377-82. PubMed ID: 10402974
[TBL] [Abstract][Full Text] [Related]
19. Vaccines for preventing malaria.
Graves P; Gelband H
Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
